EMV Capital (AIM:EMVC, FRA:NTK1) CEO Dr Ilian Iliev talked with Proactive's Stephen Gunnion about Vortex Biotech’s advancement in liquid biopsy technology and how the company fits within its "venture building" strategy.
Iliev explained that Vortex addresses a significant public healthcare need in early cancer diagnostics, particularly as the industry shifts away from traditional tissue biopsies toward liquid biopsy approaches. He highlighted that tissue biopsies are often painful, costly, and limited in frequency, whereas liquid biopsies offer a less invasive and more scalable alternative.
Vortex managing director Paul Reeves described how the Vortex platform supports precision medicine by delivering precise and comprehensive tumour biology information. Unlike antibody- or magnet-based systems, the Vortex platform uses a purely physics-based microfluidics approach to isolate circulating tumour cells (CTCs), avoiding selection bias and preserving cell integrity.
Reeves said: “We are uniquely gentle on the cell… you can turn one circulating tumour cell into a million cells.” This capability enables potential applications in drug discovery and drug testing, opening additional market opportunities beyond early diagnostics.
The company has also been selected for AstraZeneca’s expanded exchange program, providing validation of its science and strategy, alongside partnerships including Europe’s largest private pathology laboratory. Vortex Biotech is currently midway through global clinical validation studies and is progressing toward regulatory submissions and broader UK and European commercial rollout.
For more interviews like this, visit Proactive’s YouTube channel, give this video a like, subscribe to the channel and enable notifications so you don’t miss future content.
#EMVCapital #VortexBiotech #LiquidBiopsy #CancerDiagnostics #PrecisionMedicine #CirculatingTumorCells #OncologyInnovation #Microfluidics #DrugDiscovery #ClinicalValidation #HealthcareInnovation #BiotechInvesting
